Clinically Proven to Deliver Superior Results
Minitouch has demonstrated exceptional patient outcomes in clinical trials and real-world use, offering long-term relief from heavy bleeding and period pain while maintaining an impeccable safety record.
With a lower reintervention rate and higher success rates than other endometrial ablation devices, Minitouch sets a new standard for patient satisfaction, safety, and effectiveness.
Unmatched Results for Bleeding, Pain, and Quality of Life
Minitouch consistently delivers high rates of success across key clinical outcomes, including:
These results prove that Minitouch is more effective than second-generation endometrial ablation devices while being gentler and easier to perform.
No device failures across all clinical trials
No major adverse events or long-term complications
Safer for more women—even those with prior C-sections or larger uterine cavities
Impeccable Safety Record
Minitouch has been extensively studied in both the U.K. and U.S., with data confirming:
By eliminating the risks associated with high-temperature ablation, cervical dilation, and general anesthesia, Minitouch provides one of the safest endometrial ablation options available today.
Low Reintervention Rate—Long-Lasting Results
Unlike some other ablation devices that require repeat procedures, Minitouch delivers long-term success with minimal reinterventions:
With a lower reintervention rate than second-generation GEA devices, Minitouch ensures that patients get long-lasting relief with a single treatment.
With unsurpassed outcomes in bleeding reduction,
pain relief, and patient satisfaction, Minitouch is the safest, most effective in-office endometrial ablation solution available today.